RL1

General Information


DRACP ID  DRACP00593

Peptide Name   RL1

Sequence  RLLRLLRRLLRLLR

Sequence Length  14

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma IC50=3.7±0.1 μM MTT assay 24h 1
MCF-7 Invasive breast carcinoma of no special type Carcinoma IC50=2.5±0.3 μM MTT assay 24h 1
A549 Lung adenocarcinoma Carcinoma IC50=4.3±0.2 μM MTT assay 24h 1

Hemolytic Activity  Mice red blood cells: HD50=2.9±0.3 μM

Normal (non-cancerous) Cytotoxicity  HLF: IC50=6.3±0.2 μM; 293T: IC50=9.6±1.4 μM; HUVEC: IC50=8.4±0.6 μM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00593

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C84H162N32O15

Absent amino acids  ACDEFGHIKMNPQSTVWY

Common amino acids  L

Mass  209248

Pl  13.2

Basic residues  6

Acidic residues  0

Hydrophobic residues  8

Net charge  6

Boman Index  -5016

Hydrophobicity  24.29

Aliphatic Index  222.86

Half Life 
  Mammalian: 1 hour
  Yeast: 2 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 27195657

Title  Amphipathicity Determines Different Cytotoxic Mechanisms of Lysine- or Arginine-Rich Cationic Hydrophobic Peptides in Cancer Cells

Doi 10.1021/acs.jmedchem.5b02016

Year  2016

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.